Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

ClinicalTrials.gov ID: NCT04855747

Public ClinicalTrials.gov record NCT04855747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.

Study identification

NCT ID
NCT04855747
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Levomecor Inc.
Industry
Enrollment
236 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 29, 2021
Primary completion
Dec 30, 2024
Completion
Jan 13, 2025
Last update posted
Jul 9, 2026

2021 – 2025

United States locations

U.S. sites
70
U.S. states
28
U.S. cities
62
Facility City State ZIP Site status
Relmada Site Homewood Alabama 35209
Relmada Site Chandler Arizona 85226
Relmada Site Chandler Arizona 85286
Relmada Site Phoenix Arizona 85016
Relmada Site Tucson Arizona 85704
Relmada Site Bryant Arkansas 72022
Relmada Site Anaheim California 92805
Relmada Site Bellflower California 90706
Relmada Site Encino California 91316
Relmada Site Lafayette California 94549
Relmada Site Los Angeles California 90015
Relmada Site Newport Beach California 92660
Relmada Site Orange California 92868
Relmada Site Redlands California 92374
Relmada Site Santa Ana California 92705
Relmada Site Stanford California 94305
Relmada Site Temecula California 92591
Relmada Site Upland California 91786
Relmada Site Denver Colorado 80209
Relmada Site Brandon Florida 33511
Relmada Site Hialeah Florida 33015
Relmada Site Jacksonville Florida 32256
Relmada Site Maitland Florida 32751
Relmada Site Miami Florida 33122
Relmada Site Miami Florida 33125
Relmada Site Miami Florida 33133
Relmada Site Miami Florida 33136
Relmada Site Miami Florida 33174
Relmada Site Miami Springs Florida 33166
Relmada Site Okeechobee Florida 34972
Relmada Site Tampa Florida 33607
Relmada Site West Palm Beach Florida 33407
Relmada Site Savannah Georgia 31406
Relmada Site Boise Idaho 83704
Relmada Site Chicago Illinois 60611
Relmada Site Chicago Illinois 60634
Relmada Site Elgin Illinois 60123
Relmada Site Overland Park Kansas 66210
Relmada Site Marrero Louisiana 70072
Relmada Site Baltimore Maryland 21208
Relmada Site Bel Air Maryland 21015
Relmada Site Gaithersburg Maryland 20877
Relmada Site Boston Massachusetts 02131
Relmada Site Bloomfield Hills Michigan 48302
Relmada Site Mankato Minnesota 56001
Relmada Site Weldon Spring Missouri 63304
Relmada Site Las Vegas Nevada 89121
Relmada Site Toms River New Jersey 08755
Relmada Site Cedarhurst New York 11516
Relmada Site Monroe North Carolina 28112
Relmada Site Beachwood Ohio 44122
Relmada Site Cincinnati Ohio 45215
Relmada Site Cincinnati Ohio 45219
Relmada Site Westlake Ohio 44145
Relmada Site Philadelphia Pennsylvania 19104
Relmada Site State College Pennsylvania 16801
Relmada Site Memphis Tennessee 38119
Relmada Site Austin Texas 78737
Relmada Site Austin Texas 78759
Relmada Site Beaumont Texas 77702
Relmada Site Bellaire Texas 77401
Relmada Site Dallas Texas 75243
Relmada Site Friendswood Texas 77546
Relmada Site Houston Texas 77081
Relmada Site Sherman Texas 75092
Relmada Site Wichita Falls Texas 76309
Relmada Site Draper Utah 84020
Relmada Site Rutland Vermont 05701
Relmada Site Portsmouth Virginia 23703
Relmada Site Everett Washington 98201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04855747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 9, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04855747 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →